Shionogi, Inc
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Clinical Trials
76
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (72 trials with phase data)• Click on a phase to view related trials
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
- Conditions
- Renal Impairment
- Interventions
- Drug: S-892216-PO
- First Posted Date
- 2025-10-17
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 40
- Registration Number
- NCT07217886
- Locations
- 🇺🇸
Orlando Clicinal Research Center, Orlando, Florida, United States
🇺🇸Global Clinical Professionals (GCP) LLC, St. Petersburg, Florida, United States
🇺🇸Genesis Clinical Research, Tampa, Florida, United States
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 192
- Registration Number
- NCT07214571
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 45
- Registration Number
- NCT07123155
- Locations
- 🇺🇸
University of California - Irvine Medical Center, Irvine, California, United States
🇺🇸University of Florida (UF) - Gainesville, Gainesville, Florida, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: S-892216-LAIDrug: Placebo
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 98
- Registration Number
- NCT07093580
- Locations
- 🇺🇸
ICON Clinical Research: Lenexa, Lenexa, Kansas, United States
🇺🇸ICON Clinical Research: Salt Lake City, Salt Lake City, Utah, United States
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 32
- Registration Number
- NCT07018492
- Locations
- 🇺🇸
Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
Shionogi's Cefiderocol Shows Superior Outcomes When Used as Early Treatment for Drug-Resistant Infections
Real-world data from the PROVE study demonstrates that cefiderocol achieved a 73.7% clinical cure rate when used as empiric treatment compared to 54.3% when used as salvage therapy for serious gram-negative bacterial infections.
Dovato Demonstrates Non-Inferior Efficacy to Biktarvy with Significantly Less Weight Gain in 96-Week HIV Treatment Study
ViiV Healthcare's PASO DOBLE trial shows Dovato (DTG/3TC) maintains viral suppression as effectively as Biktarvy (BIC/FTC/TAF) at 96 weeks in 553 virologically suppressed HIV-1 patients.
Early Long COVID Trials of Paxlovid and Monoclonal Antibodies Show No Significant Benefits, But Research Continues
Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.
ViiV Healthcare Presents Real-World Data on Long-Acting HIV Treatments at IAS 2025
ViiV Healthcare presented extensive real-world data at IAS 2025 demonstrating the effectiveness, safety, and tolerability of its long-acting injectable HIV treatments, including cabotegravir + rilpivirine LA for treatment and cabotegravir LA for prevention.
Stallergenes Greer Transitions Actair® Promotional Activities from Shionogi to CEOLIA in Japan
Stallergenes Greer has appointed CEOLIA Pharma as its new promotional partner for Actair® in Japan, ending a 15-year licensing agreement with Shionogi that began in 2010.
BioVersys and Shionogi Form Strategic Partnership to Develop Novel NTM Treatments Worth Up to CHF 484 Million
BioVersys and Shionogi have entered a research collaboration and exclusive license option agreement to develop novel ansamycin leads from BioVersys' BV500 program targeting non-tuberculous mycobacteria infections.
Shionogi and Cilcare Partner in €400M Deal to Develop Novel Hearing Loss Treatments
Shionogi has entered into a joint research agreement with Cilcare to develop innovative treatments for hearing loss, a condition affecting 5% of the global population with no effective treatments currently available.
Shionogi to Acquire Japan Tobacco's Pharma Units for $1.1 Billion
Japanese pharmaceutical company Shionogi has announced a $1.1 billion acquisition of Torii Pharmaceutical and other pharmaceutical assets from Japan Tobacco, marking a significant consolidation in the Japanese pharma sector.
F2G's Novel Antifungal Olorofim Shows Promise Despite FDA Setback, Phase 2b Results Published in The Lancet
F2G's olorofim, the first in a new class of orotomide antifungals, received a complete response letter from the FDA requiring additional data before approval.